84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]施振宇,劉鐘,陳文亮,等.中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究[J].中醫(yī)正骨,2017,29(04):1-7.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(04):1-7.
點(diǎn)擊復(fù)制

中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第29卷
期數(shù):
2017年04期
頁碼:
1-7
欄目:
臨床研究
出版日期:
2017-04-20

文章信息/Info

Title:
A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia
作者:
施振宇1; 劉鐘1; 陳文亮1; 毛一凡1; 張佳鋒1; 李春雯1; 劉康2; 吳連國(guó)2; 史曉林2
1.浙江中醫(yī)藥大學(xué),浙江 杭州 310053; 2.浙江省新華醫(yī)院,浙江 杭州 310005
Author(s):
SHI Zhenyu1; LIU Zhong1; CHEN Wenliang1; MAO Yifan1; ZHANG Jiafeng1; LI Chunwen1; LIU Kang2; WU Lianguo2; SHI Xiaolin2
1.Zhejiang Chinese Medical University,Hangzhou 310053,Zhejiang,China 2.Xinhua Hospital of Zhejiang Province, Hangzhou 310005,Zhejiang,China
關(guān)鍵詞:
骨質(zhì)疏松; 絕經(jīng)后;  骨量減少;  強(qiáng)骨飲;  五禽戲;  日光療法;  骨密度;  Ⅰ型前膠原氨基端前肽;  Ⅰ型膠原羧基端肽β特殊序列;  臨床試驗(yàn)
Keywords:
Key words osteoporosis; postmenopausal;  osteopenia;  Qianggu Yin;  five mimic-animal boxing;  heliotherapy;  bone density;  N-terminal propeptide of typeⅠprecollagen;  β cross-linked C-telopeptides of typeⅠcollagen;  clinical trial
摘要:
觀察口服強(qiáng)骨飲顆粒聯(lián)合新編五禽戲鍛煉及佩戴藥穴腰帶的中醫(yī)綜合療法防治絕經(jīng)后骨量減少的臨床療效及安全性。方法:從6家醫(yī)院共納入800例絕經(jīng)后骨量減少患者,其中400例患者進(jìn)行日光浴和飲食干預(yù)(常規(guī)治療組),其余400例患者在此基礎(chǔ)上采用口服強(qiáng)骨飲顆粒聯(lián)合新編五禽戲鍛煉及佩戴藥穴腰帶的中醫(yī)綜合治療(中醫(yī)綜合治療組),共治療12個(gè)月。觀察骨密度(bone mineral density,BMD)、血清Ⅰ型前膠原氨基端前肽(N-terminal propeptide of typeⅠprecollagen,PⅠNP)和Ⅰ型膠原羧基端肽β特殊序列(β cross-linked C-telopeptides of typeⅠcollagen,β-CTX)含量、疼痛視覺模擬量表(visual analogue scale,VAS)評(píng)分及不良事件發(fā)生率。結(jié)果:①BMD測(cè)定結(jié)果。治療前后不同時(shí)間點(diǎn)腰椎BMD的差異有統(tǒng)計(jì)學(xué)意義,即存在時(shí)間效應(yīng)(F=1 974.342,P=0.000); 治療后中醫(yī)綜合治療組腰椎BMD逐漸升高(F=1 482.684,P=0.000),常規(guī)治療組腰椎BMD先升高然后降低(F=1 161.076,P=0.000)。2組患者腰椎BMD總體比較,組間差異無統(tǒng)計(jì)學(xué)意義,即不存在分組效應(yīng)(F=2.939,P=0.087)。治療前,2組患者腰椎BMD的差異無統(tǒng)計(jì)學(xué)意義[(0.775±0.046)g·cm-2,(0.777±0.049)g·cm-2,t=0.416,P=0.677]; 治療6個(gè)月后和12個(gè)月后,中醫(yī)綜合治療組的腰椎BMD均大于常規(guī)治療組[(0.788±0.047)g·cm-2,(0.780±0.049)g·cm-2,t=-2.487,P=0.013;(0.789±0.048)g·cm-2,(0.778±0.049)g·cm-2,t=-3.039,P=0.002]。時(shí)間因素和分組因素存在交互效應(yīng)(F=958.556,P=0.000)。治療前后不同時(shí)間點(diǎn)股骨近端BMD的差異有統(tǒng)計(jì)學(xué)意義,即存在時(shí)間效應(yīng)(F=2 639.694,P=0.000); 治療后中醫(yī)綜合治療組股骨近端BMD逐漸升高[(0.704±0.056)g·cm-2,(0.709±0.057)g·cm-2,(0.713±0.057)g·cm-2,F=5 515.964,P=0.000],常規(guī)治療組股骨近端BMD逐漸降低[(0.707±0.054)g·cm-2,(0.706±0.054)g·cm-2,(0.706±0.054)g·cm-2,F=470.256,P=0.000]。2組患者股骨近端BMD總體比較,組間差異無統(tǒng)計(jì)學(xué)意義,即不存在分組效應(yīng)(F=0.301,P=0.583)。時(shí)間因素和分組因素存在交互效應(yīng)(F=5 456.814,P=0.000)。②血清PⅠNP和β-CTX含量測(cè)定結(jié)果。治療前后不同時(shí)間點(diǎn)血清PⅠNP含量的差異有統(tǒng)計(jì)學(xué)意義,即存在時(shí)間效應(yīng)(F=276.541,P=0.000); 治療后中醫(yī)綜合治療組血清PⅠNP含量先降低后升高,常規(guī)治療組血清PⅠNP含量逐漸降低。2組患者血清PⅠNP含量總體比較,組間差異有統(tǒng)計(jì)學(xué)意義,即存在分組效應(yīng)(F=11.094,P=0.001); 治療前,2組患者血清PⅠNP含量的差異無統(tǒng)計(jì)學(xué)意義[(45.76±21.66)ng·mL-1,(45.34±19.95)ng·mL-1,t=-0.284,P=0.777]; 治療6個(gè)月后和12個(gè)月后,中醫(yī)綜合治療組的血清PⅠNP含量均高于常規(guī)治療組[(43.58±20.67)ng·mL-1,(40.58±17.81)ng·mL-1,t=-2.052,P=0.040;(49.89±24.16)ng·mL-1,(38.83±17.09)ng·mL-1,t=-7.472,P=0.000)]。時(shí)間因素和分組因素存在交互效應(yīng)(F=651.242,P=0.000)。治療前后不同時(shí)間點(diǎn)血清β-CTX含量的差異有統(tǒng)計(jì)學(xué)意義,即存在時(shí)間效應(yīng)(F=316.946,P=0.000); 治療后中醫(yī)綜合治療組血清β-CTX含量先降低后升高[(0.296±0.173)ng·mL-1,(0.227±0.137)ng·mL-1,(0.259±0.155)ng·mL-1,F=275.302,P=0.000],常規(guī)治療組血清β-CTX含量逐漸降低[(0.287±0.158)ng·mL-1,(0.281±0.156)ng·mL-1,(0.273±0.151)ng·mL-1,F=992.78,P=0.000]。2組患者血清β-CTX含量總體比較,組間差異無統(tǒng)計(jì)學(xué)意義,即不存在分組效應(yīng)(F=3.124,P=0.078)。治療前和治療12個(gè)月后,2組患者血清β-CTX含量的差異均無統(tǒng)計(jì)學(xué)意義(t=-0.880,P=0.379; t=1.257,P=0.209); 治療6個(gè)月后,中醫(yī)綜合治療組血清β-CTX含量低于常規(guī)治療組(t=5.233,P=0.000)。時(shí)間因素和分組因素存在交互效應(yīng)(F=247.222,P=0.000)。③疼痛VAS評(píng)分測(cè)定結(jié)果。治療前和治療12個(gè)月后,2組患者疼痛VAS評(píng)分比較,差異均無統(tǒng)計(jì)學(xué)意義[(2.40±0.69)分,(2.39±0.70)分,t=0.335,P=0.723;(2.38±0.68)分,(2.46±0.67)分,t=-1.696,P=0.090]; 2組患者治療前的疼痛VAS評(píng)分與治療12個(gè)月后相比,差異均無統(tǒng)計(jì)學(xué)意義(t=0.508,P=0.612; t=-1.540,P=0.124)。④不良事件觀察結(jié)果。至試驗(yàn)結(jié)束時(shí)中醫(yī)綜合治療組失訪19例、未按照試驗(yàn)方案治療28例,常規(guī)治療組失訪13例、未按照試驗(yàn)方案治療9例,脫落和剔除均發(fā)生在治療6個(gè)月后數(shù)據(jù)采集完成之后。2組均無患者死亡、發(fā)生嚴(yán)重疾病等嚴(yán)重不良事件。結(jié)論:口服強(qiáng)骨飲顆粒聯(lián)合新編五禽戲鍛煉及佩戴藥穴腰帶的中醫(yī)綜合療法,能提高絕經(jīng)后骨量減少患者血清中PⅠNP含量、降低β-CTX含量,從而增加患者的骨密度,而且安全性較高。
Abstract:
ABSTRACT Objective:To observe the clinical curative effects and safety of complex therapy of traditional Chinese medicine(TCM)for prevention and treatment of postmenopausal osteopenia.Methods:Eight hundred patients with postmenopausal osteopenia were recruited from 6 hospitals and randomly divided into conventional therapy group and TCM complex therapy group,400 cases in each group.All patients in both of the 2 groups were treated with sunbathing and dietary intervention,meanwhile,the patients in TCM complex therapy group were treated with oral application of Qianggu Yin Keli(強(qiáng)骨飲顆粒,QGYKL)combined with modified five mimic-animal boxing exercises and wearing lumbar balteum with TCM unguentum applied to acupoints for 12 months.The bone mineral density(BMD),serum contents of N-terminal propeptide of typeⅠprecollagen(PⅠNP)and β cross-linked C-telopeptides of typeⅠcollagen(β-CTX),visual analogue scale(VAS)scores and adverse events incidence were observed.Results:There was statistical difference in the lumbar vertebra BMD between different timepoints before and after the treatment,in other words,there was time effect(F=1 974.342,P=0.000).The lumbar vertebra BMD increased gradually after the treatment in TCM complex therapy group(F=1 482.684,P=0.000),while the lumbar vertebra BMD increased at first and then decreased in conventional therapy group(F=1 161.076,P=0.000).There was no statistical difference in the lumbar vertebra BMD between the 2 groups in general,in other words,there was no group effect(F=2.939,P=0.087).There was no statistical difference in the lumbar vertebra BMD between the 2 groups before treatment(0.775+/-0.046 vs 0.777+/-0.049 g/cm(2),t=0.416,P=0.677).The lumbar vertebra BMD was greater in TCM complex therapy group compared to conventional therapy group after 6- and 12-month treatment(0.788+/-0.047 vs 0.780+/-0.049 g/cm(2),t=-2.487,P=0.013; 0.789+/-0.048 vs 0.778+/-0.049 g/cm(2),t=-3.039,P=0.002).There was interaction between time factor and group factor(F=958.556,P=0.000).There was statistical difference in the proximal femoral BMD between different timepoints before and after the treatment,in other words,there was time effect(F=2 639.694,P=0.000).The proximal femoral BMD increased gradually after the treatment in TCM complex therapy group(0.704+/-0.056,0.709+/-0.057,0.713+/-0.057 g/cm(2),F=5 515.964,P=0.000),while the proximal femoral BMD decreased gradually in conventional therapy group(0.707+/-0.054,0.706+/-0.054,0.706+/-0.054 g/cm(2),F=470.256,P=0.000).There was no statistical difference in the proximal femoral BMD between the 2 groups in general,in other words,there was no group effect(F=0.301,P=0.583).There was interaction between time factor and group factor(F=5 456.814,P=0.000).There was statistical difference in the serum contents of PⅠNP between different timepoints before and after the treatment,in other words,there was time effect(F=276.541,P=0.000).The serum contents of PⅠNP decreased at first and then increased after the treatment in TCM complex therapy group,while the serum contents of PⅠNP decreased gradually in conventional therapy group.There was statistical difference in the serum contents of PⅠNP between the 2 groups in general,in other words,there was group effect(F=11.094,P=0.001).There was no statistical difference in the serum contents of PⅠNP between the 2 groups before treatment(45.76+/-21.66 vs 45.34+/-19.95 ng/ml,t=-0.284,P=0.777).The serum contents of PⅠNP was higher in TCM complex therapy group compared to conventional therapy group after 6- and 12-month treatment(43.58+/-20.67 vs 40.58+/-17.81 ng/ml,t=-2.052,P=0.040; 49.89+/-24.16 vs 38.83+/-17.09 ng/ml,t=-7.472,P=0.000).There was interaction between time factor and group factor(F=651.242,P=0.000).There was statistical difference in the serum contents of β-CTX between different timepoints before and after the treatment,in other words,there was time effect(F=316.946,P=0.000).The serum contents of β-CTX decreased at first and then increased after the treatment in TCM complex therapy group(0.296+/-0.173,0.227+/-0.137,0.259+/-0.155 ng/ml,F=275.302,P=0.000),while the serum contents of β-CTX decreased gradually in conventional therapy group(0.287+/-0.158,0.281+/-0.156,0.273+/-0.151 ng/ml,F=992.78,P=0.000).There was no statistical difference in the serum contents of β-CTX between the 2 groups in general,in other words,there was no group effect(F=3.124,P=0.078).There was no statistical difference in the serum contents of β-CTX between the 2 groups before treatment and after 12-month treatment(t=-0.880,P=0.379; t=1.257,P=0.209).The serum contents of β-CTX was lower in TCM complex therapy group compared to the conventional therapy group after 6-month treatment(t=5.233,P=0.000).There was interaction between time factor and group factor(F=247.222,P=0.000).There was no statistical difference in the VAS scores between the 2 groups before treatment and after 12-month treatment(2.40+/-0.69 vs 2.39+/-0.70 points,t=0.335,P=0.723; 2.38+/-0.68 vs 2.46+/-0.67 points,t=-1.696,P=0.090).There was no statistical difference in the VAS scores between pre-treatment and after 12-month treatment in the 2 groups(t=0.508,P=0.612; t=-1.540,P=0.124).Nineteen patients in TCM complex therapy group and 13 patients in conventional therapy group lost to follow-up,and 28 patients in TCM complex therapy group and 9 patients in conventional therapy group did not keep to the scheme of trial after 6-month treatment.However,their relevant data were collected and recorded.No severe adverse events such as death and severe diseases were found in both of the 2 groups.Conclusion:TCM complex therapy,including oral application of QGYKL combined with modified five mimic-animal boxing exercises and wearing lumbar balteum with TCM unguentum applied to acupoints,can increase the BMD through increasing the serum contents of PⅠNP and decrease the serum contents of β-CTX in patients with postmenopausal osteopenia,meanwhile it has high safty.

參考文獻(xiàn)/References:

[1] 劉忠厚.骨質(zhì)疏松診斷[M].北京:中國(guó)現(xiàn)代文藝出版社,2011:357.
[2] 中華醫(yī)學(xué)會(huì)骨質(zhì)疏松和骨礦鹽疾病分會(huì).原發(fā)性骨質(zhì)疏松癥診治指南(2011年)[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2011,4(1):2-17.
[3] 高輝,徐苓.強(qiáng)骨膠囊治療原發(fā)性骨質(zhì)疏松癥、骨量減少的療效及安全性評(píng)價(jià)[J].中國(guó)骨質(zhì)疏松雜志,2011,17(8):727-730.
[4] 孔令成,施振宇,姚建亮,等.強(qiáng)骨飲治療骨質(zhì)疏松性椎體壓縮性骨折的臨床研究[J].中國(guó)骨質(zhì)疏松雜志,2016,22(9):1159-1163.
[5] 林華,陳新,朱秀芬,等.生活方式調(diào)整干預(yù)絕經(jīng)后骨量減少[J].中國(guó)骨質(zhì)疏松雜志,2008,14(6):409-413.
[6] 吳連國(guó),劉康,黃俊俊,等.強(qiáng)骨飲對(duì)股骨頸骨折患者人工股骨頭置換術(shù)后假體周圍骨密度的影響[J].中醫(yī)正骨,2014,26(4):15-18.
[7] 何康宏,梁博程,李旭云,等.中藥穴位敷貼治療絕經(jīng)后骨質(zhì)疏松癥[J].長(zhǎng)春中醫(yī)藥大學(xué)學(xué)報(bào),2015,31(6):1240-1242.
[8] 李靜偉,潘定權(quán),何康宏,等.五禽戲防治原發(fā)性骨質(zhì)疏松癥的研究探討[J].中國(guó)骨質(zhì)疏松雜志,2014,22(7):849-853.
[9] KANIS JA.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis:synopsis of a WHO report.WHO Study Group[J].Osteoporos Int,1994,4(6):368-381.
[10] LEE WT,CHEUNG CS,TSE YK,et al.Generalized low bone mass of girls with adolescent idiopathic scoliosis is related to inadequate Calcium intake and weight bearing physical activity in peripubertal period[J].Osteoporos Int,2005,16(9):1024-1035.
[11] BITTO A,BURNETT BP,POLITO F,et al.Effects of genistein aglycone in osteoporotic,ovariectomized rats:a comparison with alendronate, raloxifene and oestradiol[J].Br J Pharmacol,2008,155(6):896-905.
[12] 李國(guó)德.骨質(zhì)疏松癥的中醫(yī)藥治療概述[J].中國(guó)老年保健醫(yī)學(xué),2010,8(4):69-70.
[13] 孔令成,施振宇,姚建亮,等.強(qiáng)骨飲治療骨質(zhì)疏松性椎體壓縮性骨折的臨床研究[J].中國(guó)骨質(zhì)疏松雜志,2016,22(9):1159-1163.
[14] 李春雯,史曉林.益氣溫經(jīng)方防治絕經(jīng)后骨質(zhì)疏松性髖部骨折的骨密度及SF-36療效評(píng)價(jià)[J].中國(guó)現(xiàn)代應(yīng)用藥學(xué),2015,32(5):592-595.
[15] 丁璟琳,潘定權(quán),李靜偉,等.骨質(zhì)疏松貼治療原發(fā)型骨質(zhì)疏松癥100例[J].中國(guó)中醫(yī)骨傷科雜志,2014,22(6):41-42.
[16] 謝燕,曹海云,喻長(zhǎng)純.影響人體增高的因素及疾病的防治辦法[M].北京:中國(guó)人口出版社,2016:123.
[17] 李靜偉,潘定權(quán),何康宏,等.改良五禽戲防治原發(fā)Ⅰ型骨質(zhì)疏松癥的臨床應(yīng)用體會(huì)[J].中國(guó)骨質(zhì)疏松雜志,2014,20(8):920-923.

相似文獻(xiàn)/References:

[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]李學(xué)朋,朱立國(guó).骨疏康膠囊對(duì)去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(04):12.
[3]陳冠軍,陳揚(yáng),莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[4]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(04):27.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對(duì)絕經(jīng)后骨質(zhì)疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(04):19.
[6]項(xiàng)旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(04):20.
[7]史曉林,李春雯,張志強(qiáng).弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時(shí)間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(04):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機(jī)制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(04):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的 相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(04):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質(zhì)疏松癥辨證分型與抑郁焦慮的關(guān)系研究[J].中醫(yī)正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(04):3.
[11]韓艷,溫利平,劉娜,等.補(bǔ)腎活血方對(duì)去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補(bǔ)腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(04):7.
[12]歐國(guó)峰,劉鑫,董博,等.絕經(jīng)后骨質(zhì)疏松癥的免疫學(xué)研究進(jìn)展[J].中醫(yī)正骨,2016,28(08):70.
[13]梁文娜,李西海,李燦東.血清microRNA與絕經(jīng)后骨質(zhì)疏松癥腎虛證的關(guān)系[J].中醫(yī)正骨,2017,29(10):53.
[14]梁文娜,李西海,胡柳,等.二至丸抑制絕經(jīng)后骨質(zhì)疏松大鼠骨代謝紊亂的作用機(jī)制研究[J].中醫(yī)正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(04):1.
[15]劉晨,李興勇,姚興璋,等.絕經(jīng)后骨質(zhì)疏松癥的流行病學(xué)概況及發(fā)病機(jī)制研究進(jìn)展[J].中醫(yī)正骨,2018,30(03):52.
[16]楊依然,劉鐘,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳動(dòng)物雷帕霉素靶蛋白通路參與絕經(jīng)后骨質(zhì)疏松癥發(fā)生發(fā)展過程中細(xì)胞自噬的機(jī)制[J].中醫(yī)正骨,2018,30(04):59.
[17]曹俊青,鄭劍南,張麟.右歸丸聯(lián)合阿侖膦酸鈉口服治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證的臨床研究[J].中醫(yī)正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右歸丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(04):20.
[18]李中萬,徐紹俊,楊廣鋼,等.健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ) 治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證[J].中醫(yī)正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(04):11.
[19]趙凡,劉全,吳連國(guó).口服強(qiáng)骨飲聯(lián)合碳酸鈣D3片治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(強(qiáng)骨飲)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(04):26.
[20]史曉林,楊依然,劉鐘,等.基于蛋白質(zhì)組學(xué)方法分析絕經(jīng)后骨質(zhì)疏松癥全血差異蛋白[J].中醫(yī)正骨,2019,31(06):7.
　SHI Xiaolin,YANG Yiran,LIU Zhong,et al.Analysis of proteins which are differentially expressed in whole blood of patients with postmenopausal osteoporosis using proteomics approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(04):7.

備注/Memo

備注/Memo:
基金項(xiàng)目:國(guó)家中醫(yī)藥管理局中醫(yī)藥行業(yè)科研專項(xiàng)項(xiàng)目(201307010) 通訊作者:史曉林 E-mail:[email protected]
更新日期/Last Update: 1900-01-01